Clinical trials
Pulmonary Disease, Chronic Obstructive trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 53 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 13 |
| AstraZeneca | 12 |
| Boehringer Ingelheim | 7 |
| GlaxoSmithKline | 3 |
| Novartis | 3 |
| Pfizer | 3 |
| Sanofi | 3 |
| All India Institute of Medical Sciences | 2 |
| Eli Lilly and Company | 2 |
| Hoffmann-La Roche | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Disease, Chronic Obstructive | 66 |
| Asthma | 2 |
| Bronchitis, Chronic | 2 |
| Cardiovascular Diseases | 2 |
| Diabetes Mellitus | 2 |
| Emphysema | 2 |
| Hypertension | 2 |
| Lung Diseases | 2 |
| Lung Diseases, Obstructive | 2 |
| Pneumonia | 2 |
Trials
Showing 26 to 50 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.